What is Lifesci Capital’s Forecast for AVDL Q2 Earnings?

Avadel Pharmaceuticals PLC. (NASDAQ:AVDL) – Lifesci Capital issued their Q2 2026 earnings estimates for shares of Avadel Pharmaceuticals in a report issued on Wednesday, September 3rd. Lifesci Capital analyst F. Brisebois anticipates that the company will earn $0.19 per share for the quarter. Lifesci Capital has a “Strong-Buy” rating on the stock. The consensus estimate for Avadel Pharmaceuticals’ current full-year earnings is ($0.51) per share. Lifesci Capital also issued estimates for Avadel Pharmaceuticals’ Q3 2026 earnings at $0.23 EPS, Q4 2026 earnings at $0.23 EPS and FY2026 earnings at $0.73 EPS.

A number of other brokerages have also commented on AVDL. UBS Group increased their price objective on shares of Avadel Pharmaceuticals from $13.00 to $20.00 and gave the stock a “buy” rating in a report on Thursday, August 21st. Wall Street Zen raised shares of Avadel Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 9th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of Avadel Pharmaceuticals in a research note on Friday, August 8th. Zacks Research raised shares of Avadel Pharmaceuticals to a “strong-buy” rating in a research note on Friday, August 8th. Finally, HC Wainwright raised their target price on shares of Avadel Pharmaceuticals from $24.00 to $36.00 and gave the company a “buy” rating in a research note on Friday. Two equities research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $20.86.

Avadel Pharmaceuticals Stock Up 5.1%

Shares of NASDAQ:AVDL opened at $15.76 on Thursday. Avadel Pharmaceuticals has a 12 month low of $6.38 and a 12 month high of $16.66. The company’s 50-day moving average price is $12.00 and its two-hundred day moving average price is $9.74. The firm has a market cap of $1.53 billion, a P/E ratio of -525.33 and a beta of 1.58.

Avadel Pharmaceuticals (NASDAQ:AVDL) last issued its quarterly earnings data on Thursday, August 7th. The company reported $0.10 EPS for the quarter, topping analysts’ consensus estimates of $0.02 by $0.08. Avadel Pharmaceuticals had a negative net margin of 1.32% and a negative return on equity of 3.73%. The firm had revenue of $68.13 million for the quarter, compared to analyst estimates of $60.28 million. During the same quarter in the prior year, the firm earned ($0.14) EPS. The company’s revenue was up 64.1% on a year-over-year basis. Avadel Pharmaceuticals has set its FY 2025 guidance at EPS.

Institutional Trading of Avadel Pharmaceuticals

A number of hedge funds have recently modified their holdings of the company. Tower Research Capital LLC TRC raised its position in shares of Avadel Pharmaceuticals by 217.5% in the 2nd quarter. Tower Research Capital LLC TRC now owns 8,795 shares of the company’s stock valued at $78,000 after acquiring an additional 6,025 shares during the period. Krensavage Asset Management LLC raised its position in shares of Avadel Pharmaceuticals by 0.9% in the 2nd quarter. Krensavage Asset Management LLC now owns 958,877 shares of the company’s stock valued at $8,486,000 after acquiring an additional 8,877 shares during the period. MML Investors Services LLC raised its position in shares of Avadel Pharmaceuticals by 6.7% in the 2nd quarter. MML Investors Services LLC now owns 207,378 shares of the company’s stock valued at $1,835,000 after acquiring an additional 13,072 shares during the period. Man Group plc raised its position in shares of Avadel Pharmaceuticals by 101.3% in the 2nd quarter. Man Group plc now owns 57,931 shares of the company’s stock valued at $513,000 after acquiring an additional 29,149 shares during the period. Finally, BNP Paribas Financial Markets raised its position in shares of Avadel Pharmaceuticals by 30.8% in the 2nd quarter. BNP Paribas Financial Markets now owns 22,823 shares of the company’s stock valued at $202,000 after acquiring an additional 5,372 shares during the period. 69.19% of the stock is currently owned by institutional investors and hedge funds.

Avadel Pharmaceuticals Company Profile

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017.